Cancer BiologybioRxivPreprint
Bi-specific CAR-iNKT cell immunotherapy for high-risk KMT2A-rearranged leukemia outperforms CAR-T in an NKG2D-dependent manner and eradicates leptomeningeal disease
Hongwei Ren, Natalina Elliott, Bryan Lye…·Anastasios Karadimitris
This paper develops bi-specific CAR-iNKT cells targeting CD19 and CD133 for KMT2A-rearranged leukemia, showing superior efficacy over CAR-T in eradicating leptomeningeal disease and inducing remission.
2 citations